Local therapy for Peyronie’s disease

Szobota, Jason; Honig, Stanton C.

doi:10.1007/s11930-008-0013-x

Cited by 2 publications

(1 citation statement)

References 46 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The objective of intralesional pharmacotherapy in the treatment of Peyronie’s disease is to deliver large doses of pharmacologic agents that can have a local effect on wound remodeling, with minimal side effects. Multiple agents have been tested, including steroids, verapamil, collagenase and interferon, among others [Szobota and Honig, 2008]. These treatments are well tolerated by patients and dropout rates are quite low.…”

Section: Introductionmentioning

confidence: 99%

Intralesional collagenase in the treatment of Peyronie’s disease

Honig

2013

Therapeutic Advances in Urology

View full text Add to dashboard Cite

The objective of intralesional pharmacotherapy in the treatment of Peyronie's disease is to deliver large doses of pharmacologic agents that can have a local effect on wound remodeling, with minimal side effects. Guidelines for the treatment of peyronie's disease published in the Journal of Sexual Medicine and the European Association of Urology offer no grade A evidence of efficacy with multiple agents such as steroids, verapamil and interferon. Intralesional collagenase is the first drug to be approved by the United States Food and Drug Administration for the treatment of Peyronie's disease. This is based on grade A evidence. The purpose of this update is to review the literature and current data on intralesional collagenase in the treatment of Peyronie's disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Intralesional collagenase in the treatment of Peyronie’s disease

Honig

2013

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

Peyronie's disease: perspectives on therapeutic targets

Abdel‐Hamid¹,

Anis

2011

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Rapid translational research depends on our ability to develop rational therapies targeted to penile tunical fibrosis, which necessitate a sound knowledge of the biology, biochemistry and the physiological role of fibroblasts, myofibroblasts and stem cells in PD. Much remains to be learned about the pathogenesis of PD. Although there are many interesting therapeutic targets, we are confronted with some questions when identifying new targets, or when validating potential therapeutic options.

show abstract

Local therapy for Peyronie’s disease

Cited by 2 publications

References 46 publications

Intralesional collagenase in the treatment of Peyronie’s disease

Intralesional collagenase in the treatment of Peyronie’s disease

Peyronie's disease: perspectives on therapeutic targets

Contact Info

Product

Resources

About